Official Louisiana State Websites use .la.gov 
Secure .gov websites use HTTPS 
2022 Health Alert Network Messages
- Health Alert Network Message 23-01: CDC & FDA Identify Preliminary COVID-19 Vaccine Safety Signal for Persons Aged 65 Years and Older
- Health Alert Network Message 22-36: Important Updates on COVID-19 Therapeutics for Treatment and Prevention
- Health Alert Network Message 22- 35: Updated (Bivalent) COVID-19 Vaccines Authorized for Children Down to 6 Months of Age
- Health Alert Network Message 22- 34: FDA Authorizes and CDC Recommends Moderna and Pfizer-BioNTech Bivalent COVID19 Vaccines for Use as a Booster Dose in Younger Age Groups
- Health Alert Network Message 22- 33: Update on Ebola Virus Disease Outbreak in Central Uganda
- Health Alert Network Message 22-32: Increasing HIV Diagnoses Across Louisiana
- Health Alert Network Message 22-31: Increasing Numbers of Syphilis and Congenital Syphilis Diagnoses Across Louisiana
- Health Alert Network Message 22-30: FDA Authorizes and CDC Recommends Updated COVID19 Vaccine Boosters Targeted to be More Effective Against Current Variants
- Health Alert Network Message 22-29: Update for Louisiana Clinicians on Expanded Eligibility for JYNNEOS Vaccine and TPOXX Availability
- Health Alert Network Message 22-28: LDH Guidance for Administering Second Dose of JYNNEOS Vaccine for Monkeypox
- Health Alert Network Message 22-27: Interim Clinical Considerations for Use of JYNNEOS Vaccine during the 2022 U.S. Monkeypox Outbreak
- Health Alert Network Message 22-26: Update for Clinicians on Testing and Treatment for Monkeypox
- Health Alert Network Message 22-25: CDC and FDA Authorize Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted
- Health Alert Network Message 22-24: Update on Monkeypox Virus
- Health Alert Network Message 22-23: Update on Monkeypox Outbreak in the U.S.
- Health Alert Network Message 22-22: COVID-19 Rebound After Paxlovid Treatment
- Attachment
- Health Alert Network Message 22-21: Monkeypox Virus Infection in the United States and Other Non-endemic Countries—2022
- Health Alert Network Message 22-20: CDC and FDA Expand Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years
- Health Alert Network Message 22-19: Updated Office of Public Health Recommendations Regarding the Nationwide Infant Formula Shortage
- Health Alert Network Message 22-18: Updated COVID-19 Diagnostic Reporting Requirements
- Health Alert Network Message 22-17: FDA Updates Guidance Regarding the Janssen (Johnson & Johnson) COVID-19 Vaccine
- Health Alert Network Message 22-16: Highly Pathogenic Avian Influenza A(H5N1) Virus: Recommendations for Clinicians
- Health Alert Network Message 22-15: Updated Information on Availability and Use of Treatments for Outpatients with Mild to Moderate COVID-19 Who are at Increased Risk for Severe Outcomes of COVID-19
- Health Alert Network Message 22-14: Recommendations for Adenovirus Testing and Reporting of Children with Acute Hepatitis of Unknown Etiolog
- Health Alert Network Message 22-13: FDA Restricts Use of Monoclonal Antibody Sotrovimab to Treat COVID-19 Due to the Omicron BA.2 Variant
- Health Alert Network Message 22-12: FDA Authorizes Second Booster Dose of Pfizer-BioNTech and the Moderna COVID-19 Vaccines for People 50 and Older or People 12 and Older with Moderate or Severe Immunosuppression
- Health Alert Network Message 22-11: Powdered Infant Formula Recall Information
- Health Alert Network Message 22-10: Updated Interim Clinical Considerations for COVID-19 Vaccination Guidance
- Health Alert Network Message 22-09: Powdered Infant Formula Recall and Reporting Cases of Cronobacter sakazakii
- Health Alert Network Message 22-08: FDA Authorizes New Monoclonal Antibody for Treatment for COVID-19 that Retains Activity Against Omicron Variant
- Health Alert Network Message 22-07: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant
- Health Alert Network Message 22-06: Clarification of Recommendations for COVID-19 Vaccines for Moderately or Severely Immunocompromised People
- Health Alert Network Message 22-05: Expiration Dates of SELECT Lots of the Point-of-Care Abbott BinaxNow COVID-19 Antigen Tests EXTENDED to 15 months
- Health Alert Network Message 22-04: First Cases of Candida auris Identified in Louisiana
- Health Alert Network Message 22-03: Therapeutics for Outpatient Use in the Prevention or Treatment of COVID-19
- Health Alert Network Message 22-02: Moderna Booster Dose Interval Shortened to 5 Months
- Health Alert Network Message 22-01: New COVID-19 Vaccine Booster Dose/Additional Dose Guidance
- Health Alert Network Message 21-84: Paxlovid (nirmatrelvir tablets and ritonavir tablets) EUA and Availability
- Health Alert Network Message 21-83: Updated CDC Janssen (Johnson & Johnson) COVID-19 Vaccine Recommendations
- Health Alert Network Message 21-82: 16-and-17-Year-Olds Now Eligible for a Booster Dose of COVID-19 Vaccine
- Health Alert Network Message 21-81: B.1.1.529 (Omicron) SARS-CoV-2 Variant Message for Laboratories
- Health Alert Network Message 21-80: WHO Classifies the COVID19 Omicron Variant
- Health Alert Network Message 21-79: Memo Regarding All Individuals 18 and Over Being Eligible for COVID-19 Boosters
- Health Alert Network Message 21-78: CDC Approval of Pfizer COVID-19 Vaccine for Children 5-11 Years
- Health Alert Network Message 21-77: Moderna COVID-19 Vaccine Vial Puncture Limit
2023 Health Alert Network Messages